logo

Jazz Pharmaceuticals Plc (JAZZ)



Trade JAZZ now with
  Date
  Headline
2/26/2019 4:19:46 PM Jazz Pharma Q4 EPS $2.64 Vs. $3.79 Year Ago
12/21/2018 7:03:16 AM Jazz Receives New PDUFA Goal Date For Solriamfetol For Excessive Daytime Sleepiness Associated With Narcolepsy
11/29/2018 8:12:16 AM Jazz Says First Patient Enrolled In Phase 3 Clinical Trial On JZP-258 For Idiopathic Hypersomnia
11/9/2018 2:22:48 AM Jazz Announces Submission Of MAA To European Medicines Agency For Solriamfetol
8/27/2018 2:06:49 AM Jazz Pharma: Vyxeos Gets Marketing Authorisation In European Union For High-Risk Acute Myeloid Leukaemia
6/29/2018 4:10:03 PM Jazz Pharmaceuticals Enters Into Agreement With TerSera Therapeutics LLC For Prialt
6/29/2018 8:15:40 AM Vyxeos Receives Positive CHMP Opinion For Treatment Of Certain Types Of High-Risk Acute Myeloid Leukaemia
5/1/2018 8:52:40 AM Jazz Submits Supplemental NDA For Xyrem For Cataplexy And Excessive Daytime Sleepiness In Pediatric Narcolepsy Patients
3/2/2018 8:33:40 AM Jazz Pharma Says FDA Accepts NDA For Solriamfetol For Excessive Sleepiness Associated With Narcolepsy
2/23/2018 8:31:56 AM Jazz Pharma Announces First Patient Enrolled In Phase 2 Clinical Trial Evaluating Defibrotide
11/8/2017 10:48:59 AM RBC Capital Markets Is Cutting Jazz Pharmaceuticals plc (JAZZ) 4Q17 Estimate To 2.93 From 2.98
11/8/2017 10:48:44 AM RBC Capital Markets Is Cutting Jazz Pharmaceuticals plc (JAZZ) 4Q17 Rev. Estimate To 441.0 M From 451.0 M